Qiming-backed genomic testing firm Berry Oncology closes over $99m Series B1 round August 5, 2021 Berry Oncology, a member company of China’s Berry Genomics, raised $99.15 million in a Series B1 round of financing to double down on developing genetic testing solutions for cancer screening. China Merchants Capital, a joint venture (JV) between state-owned China Merchants Group and Asia’s warehouse operator GLP, led the new round, according to a statement on Wednesday. Existing investors Qiming Venture Partners and Legend Capital, alongside new investors Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management, Xiamen C&D Emerging Industry Equity Investment, and others also participated in the deal.